Oestradiol-17β v placebo for postmenopausal women with ischaemic stroke or transient ischaemic attack‡
| Outcomes at mean 2.8 years | Oestradiol-17β | Placebo | RRI (95% CI) | NNH |
|---|---|---|---|---|
| ‡Abbreviations defined in glossary; RRI, RRR, NNH, NNT, and CI calculated from Cox proportional hazards data in article. | ||||
| Death or non-fatal stroke | 29% | 28% | 8.3% (–17 to 32) | Not significant |
| Fatal stroke | 3.6% | 1.2% | 187% (–9.9 to 758) | Not significant |
| Transient ischaemic attack | 8.9% | 7.6% | 19% (–29 to 92) | Not significant |
| Non-fatal myocardial infarction | 4.2% | 3.7% | 20% (–50 to 143) | Not significant |
| RRR (CI) | NNT | |||
| Venous thromboembolic event | 0.89% | 1.2% | 20% (–235 to 80) | Not significant |
| Breast cancer | 1.5% | 1.5% | 0% (–243 to 70) | Not significant |